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PolymorphismBackground: The cytokines are potent inflammatory factors that regulate each stage of atherosclerosis
leading to the disease development. Interleukin-10 (IL-10) as an anti-inflammatory cytokine can develop
atherosclerosis by inhibiting the synthesis of metalloproteinase. Moreover, IL-10 promotes the plaque
stability by preserving the extracellular matrix and fibrous cap.
Aim: We evaluated the association of the two IL-10 promoter gene polymorphisms with susceptibility to
coronary artery disease (CAD) in Iranian population.
Subjects and methods: We used the Sequence Specific Primer-Polymerase Chain Reaction method to
determine genotypes. We also studied mRNA expression of the IL-10 gene in Iranian CAD patients using
quantitative real-time PCR.
Results: There was a significant association between IL-10(819) T allele and IL-10(819) T/T genotype,
and CAD (p = 0.041 and p = 0.042 respectively). There also was a significant association between IL-10
(1082) G allele and IL-10(1082) G/G genotype, and CAD (p = 0.017 and p = 0.020 respectively).
Genotype T/T of IL-10(819) polymorphism significantly associated with the two vessel disease type
(p = 0.017). In addition, there was a significant association between IL-10(1082) G/G genotype and
the three vessel disease type (p = 0.009). IL-10 mRNA expression was significantly decreased 3.36-fold
in samples with IL-10(819) polymorphism and 1.98-fold in individuals with IL-10(1082) polymor-
phism.
Conclusions: Our results suggest that IL-10 gene promoter polymorphisms may influence both coronary
artery disease risks and severity in Iranian patients.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Growing evidence confirms the role of inflammatory responses
in the pathophysiology of atherosclerotic events such as coronary
artery disease (CAD). CAD develops by plaque formation and depo-
sition in the arteries walls, causing disruption of blood flow, and is
called atherosclerosis [1]. Atherosclerosis can be stimulated by
multiple molecular pathways and genetic variants, which play a
crucial role in the determination of susceptibility to CAD [2]. Sev-
eral factors increase the risk of CAD such as age, gender, heredity,
smoking, high blood cholesterol, high blood pressure, physicalinactivity, and obesity. These factors make people prone to the
coronary heart disease [3]. The cytokines are potent inflammatory
factors that regulate each stage of atherosclerosis and leading to
the development of diseases such as CAD [4]. Interleukin-10 (IL-
10), as one of the most important anti-inflammatory cytokines,
serves as an anti-inflammatory agent by down-regulation of the
Th1 and suppression of pro-inflammatory cytokines such as IL1,
IL6, IFN-c and TNF-a [5]. It also develops atherosclerosis by
inhibiting the synthesis of metalloproteinase. Moreover, IL-10 pro-
motes the stability of plaque by preserving the extracellular matrix
and fibrous cap [2]. The IL-10 gene has variable sites (polymor-
phisms and microsatellites) which influence the level of IL-10
expression. Therefore, it may be associated directly and indirectly
with the development of the CAD. In the previous study, we eval-
uated the association of platelet-derived growth factor b polymor-
phisms with CAD [6]. In this study, we investigated the
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gene promoter and its mRNA expression level with CAD.2. Subjects and methods
2.1. Study subjects
This case-control study with randomized sampling was per-
formed to evaluate the genetic association of the two IL-10 poly-
morphisms [1082G/A (rs1800870) and 819C/T (rs1800871)]
with CAD. We enrolled 303 CAD patients with evidence of
atherosclerosis, with known number of the vessel involved, who
scheduled to undergo diagnostic coronary angiography, from
March 2013 to March 2014, in Kouwsar heart center of Golestan
University of Medical Sciences, Kordkuy, Iran. Inclusion criteria
for patients group were the presence of a stenosis less than 50%
in at least one major coronary artery. The controls group involved
343 individuals with normal coronary artery angiograms. Inclusion
criteria for the control group also were the presence of normal
electrocardiograms at rest, without symptoms of myocardial ische-
mia during exercise. In agreement with the Helsinki Declaration,
all participants were aware of the study details and signed the rel-
evant written informed consent. The Ethics Committee of Golestan
University of Medical Sciences approved this study.2.2. DNA extraction and amplification
Genomic DNA was extracted by the phenol–chloroform method
following standard protocol with some modifications as described
previously [7]. The IL-10(819)C/T and (1082)G/A polymor-
phisms were investigated by Sequences Specific Primer-
polymerase chain reaction (SSP-PCR) using two primer sets
(Table 1). PCR reaction included 2 ll of DNA, 13 ll master mix con-
taining 1.5 ll dNTP, 1.5 ll 10x buffer, 0.9 ll MgCl2, 2.2 ll 12%
Sucrose and 0.2 unit Taq Polymerase (Qiagen, Hilden, Germany),
0.5 ll human growth hormone (hGH) primer (MWG, Ebersberg,
Germany) as internal control (Table 1), 5.2 ll dH2o and 1 ll of each
specific primer (MWG, Ebersberg, Germany). The PCR reaction was
performed in a Thermal Cycler (Techne, Staffordshire, UK), with the
following program: 1 min at 95 C followed by 10 cycles of 15 s at
95 C, 50seconds at 62 C, 40 s at 72 C, followed by 20 cycles of
30 s at 95 C, 30seconds at 57 C and 30 s at 72 C with 5 min at
72 C as final extension. Then, PCR products were transferred on
1.5% agarose gel containing DNA safe stain and the bands were
visualized on a gel documentation system (UviTec, Warwickshire,
UK).Table 1
Information of primers used in this study.
Primer name [reference] Direction Sequence (50  3
IL-10 (819) C/T [8] Forward C CCCTTGTACAGG
Forward T ACCCTTGTACAG
Reverse AGGATGTGTTCC
IL-10 (1082) G/A [8] Forward G CTACTAAGGCTT
Forward A ACTAGTAAGGCT
Reverse CAGTGCGAACTG
hGH [6] Forward GCCTTCCCAACC
Reverse TCACGGATTTCT
IL-10 cDNA [9] Forward GTGATGCCCCAA
Reverse CACGGCCTTGCT
PGK1 cDNA [6] Forward GCAGATTGTGTG
Reverse CCCTAGAAGTGG2.3. Quantitative Reverse Transcriptase PCR (RT-qPCR)
Total RNA was isolated from peripheral blood mononuclear
cells (PBMCs) by the Trizol reagent (Thermo Fisher Scientific, Mas-
sachusetts, USA). In this stage, samples were selected from 80
patients and 80 normal individuals. RNA concentration was mea-
sured using a NanoDrop ND 1000 (Thermo Fisher Scientific, Mas-
sachusetts, USA). All RNA samples had a 260 nm OD equivalent
to 0.4–0.9 nanograms per microliter, and a 260/280 ratio of 1.8–
2.2. Total RNA was reversely transcribed to cDNA by the Quanti-
Tect Reverse Transcriptase kit (Qiagen, Hilden, Germany). Quanti-
tative real-time PCR was performed using a Corbett Rotor-Gene
6000 (Qiagen, Hilden, Germany) in accordance with the manufac-
turer’s instructions. The information of primers used to quantify
IL-10 mRNA expression are shown in Table 1. The phosphoglycer-
ate kinase 1 (PGK1) gene was amplified as the normalized control.
Real-time PCR was performed in triplicate using optimal condi-
tions including 3 min at 95 C as a PCR initial activation step fol-
lowed by two-step cycling at 95 C for3 s and 60 C for 30 s,
repeated for 40 cycles. The relative expression was determined
by threshold cycle (Ct) values and DDCt method as described pre-
viously [10].
2.4. Statistical analysis
All data were analyzed by GraphPad software (version 6; San
Diego, United States). Deviation from the Hardy–Weinberg
assumption was checked for each polymorphism. Comparisons of
the frequencies of the IL-10 alleles and genotypes between the
patient and control groups were carried out using a chi-square test
with Yates’ correction. Data are presented as the mean ± standard
deviation (SD) for parametric variables and as percentages for
non-parametric values. Allele and genotype frequencies were cal-
culated and compared between groups by non-parametric tests,
and followed by Fisher’s exact test. A p value of less than 0.05
was considered statistically significant.3. Results
This study consisted of 646 subjects including 303 CAD patients
and 343 normal subjects as the control group. The mean age of
cases and controls were 59.04 ± 10.61 and 52.43 ± 10.89 years
respectively. The male/female ratio was 1.50 in patients and 0.59
in controls. Deviation from the Hardy-Weinberg equation was
not observed in any of the groups (v2 < 3.84, df = 1, p < 0.05). The
allele and genotype distribution of IL-10 polymorphisms in CAD
patients and matched controls are shown in Table 3. Results of this
table show that there is a significant association between IL-10
(819) T allele, and IL-10(819) T/T genotype and CAD (p = 0.041
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type and CAD (p = 0.017 and p = 0.020 respectively). To investigate
the inheritance model of two SNP at IL-10 gene promoter, we con-
sidered three models of recessive, dominant and co-dominant.
Analysis performed in the recessive genetic model showed that
two copy of allele G of IL-10(-1082) polymorphism was required
for the increased risk [OR (95%CI): 1.60 (1.04–2.44), p = 0.032].
No significant association was observed in inheritance models of
IL-10(819) polymorphism (Table 2). The haplotype analysis of
IL-10(819) and (1082) polymorphisms showed no significant
association between haplotypes and CAD (Table 3). The genotype
frequencies in CAD group according to a number of affected arter-
ies are shown in Table 4. Results of this table show that genotype
T/T of IL-10(819) polymorphism significantly associated with the
two vessel disease type (p = 0.017). In addition, there is a signifi-
cant association between genotype G/G of IL-10(1082) polymor-
phism and the three vessel disease type (p = 0.009). The
comparison of IL-10 gene expression between CAD patients and
healthy controls are shown in Table 5. The results of this table indi-
cate that there is a significant difference in DCt values between
CAD patients and control individuals (p < 0.001). As shown in
Table 5, IL-10 mRNA expression was significantly decreased 3.36-
fold in samples with IL-10(819) polymorphism and 1.98-fold in
individuals with IL-10(1082) polymorphism.4. Discussion
CAD is a multifactorial and inflammatory disease that require
the interaction of various risk factors such as high lipid profiles,
smoking, and alcoholism [11]. IL-10 production, as an anti-
inflammatory cytokine that develop atherosclerosis, is controlled
genetically, and as previously presented, changes in IL-10 secretion
is mediated by specific IL-10 gene promoter polymorphisms
[12,13]. The analysis of genotype distribution for two IL-10 poly-
morphisms [(819)C/T and (1082)G/A] revealed that allele T in
the position of 819 from start site and allele G in the position
of 1082 may play an important role in increasing the susceptibil-
ity to CAD (Table 2). Afzal et al. study reported the association anal-
ysis of three SNP polymorphisms of IL-10 gene promoter with
Pakistani CAD patients at positions 592, 819 and 1082. InTable 2
The genotype and allele distributions of IL-10 polymorphisms in patients with CAD and co
Genotype Case, n (%) Contro
IL-10(-819)
C/C 90 (29.7) 123 (35
T/C 156 (51.5) 173 (50
T/T 57 (18.8) 47 (13.
Allele ‘‘C” 336 (55.0) 419 (61
Allele ‘‘T” 270 (45.0) 267 (39
Model of inheritance
Recessive (T/T vs. T/C + C/C)
Dominant (T/T + T/C vs. C/C)
Co-dominant (T/C vs. T/T + C/C)
IL-10(-1082)
A/A 95 (31.3) 130 (37
G/A 149 (49.2) 168 (49
G/G 59 (19.5) 45 (13.
Allele ‘‘A” 339 (55.9) 428 (62
Allele ‘‘G” 267 (44.1) 258 (37
Model of inheritance
Recessive (G/G vs. G/A + A/A)
Dominant (G/G + G/A vs. A/A)
Co-dominant (G/A vs. G/G + A/A)
OR: odds ratio; CI: Confidence Interval; N.S: Not Significant.
* A p value of less than 0.05 was considered statistically significant.agreement with our results, they showed that genotypes of IL-10
(819) T/T and IL-10(1082) G/G are significantly associated with
CAD (Table 2). In addition, Contrary to our results, they reported
that genotype of IL-10(-1082) G/A has a negative association with
CAD. A slight difference in results of two studies may be due to
the type of our cases, different ethnicities, and epigenetic effects.
They also analyzed the SNP haplotypes and in agreement with
our study (Table 3), no observed significant association between
haplotypes and CAD [14]. In Ben-hadj-Khalifa et al. study, polymor-
phisms of IL-10(819) and (1082) were investigated, and in dis-
agreement with our findings, they did not observe an association
between IL-10 polymorphisms and CAD [15]. Lio et al. study indi-
cated that the frequency of IL-10(1082) G/G genotype is signifi-
cantly higher in men than in women. Their study also showed
that patients with IL-10(1082) A/A genotype are more susceptible
to cardiovascular disease than patients with IL-10(1082) G/G
genotype [16]. Blanco et al. study suggested that allele G of IL-10
(1082) polymorphism plays no role in transcription of the IL-10
gene. Their findings showed that SNPs has a little genetic effect
on the IL-10 plasma level. Transcription of the IL-10 gene depends
on the combinations of the different polymorphisms as haplotype
[17]. In this study, the results of RT-qPCR showed a decrease in IL-
10 gene expression in CAD patients. The decrease in the IL-10
expression may increases susceptibility to CAD (Table 5). In fact,
a T to C substitution and a G to A substitution in IL-10(819) and
(1082) may activate transcription factor inhibitors and conse-
quently inhibit expression of IL-10 in. These results were partly
confirmed by the results presented in Table 4 and indicate these
genotypes may be associated with disease severity.
Genetic polymorphisms may have different effects on protein
development based on the type of tissue and cell. Therefore, more
studies are required to examine the role of IL-10 gene alleles in the
development of CAD. IL-10 is just a single player among genes
involved in atherosclerosis and thus play a minor role in the com-
plex molecular pathways in CAD. Future studies are expected to
examine with larger populations to find better understand the
disease.
In conclusion, our results suggest that IL-10 gene promoter
polymorphisms may influence both coronary artery disease risks
and severity in Iranian patients.ntrol group.
l, n (%) OR 95%CI P value
.9) 1 – –
.4) 1.23 0.85–1.77 N.S
7) 1.65 1.00–2.73 0.041*
) 1 – –




.9) 1 – –
.0) 1.21 0.86–1.71 N.S
1) 1.79 1.12–2.87 0.017*
.4) 1 – –





Haplotype frequencies of IL-10 polymorphisms in patients with CAD and control group.
Genotype combination Case, n (%) Control, n (%) OR 95%CI p value
IL-10(-1082) IL-10(-819)
A/A C/C 32 (10.6) 42 (12.2) 1 – –
C/T 45 (14.8) 63 (18.4) 0.93 0.51–1.71 N.S
T/T 18 (5.9) 25 (7.3) 0.94 0.44–2.02 N.S
G/A C/C 49 (16.2) 63 (18.4) 1.02 0.56–1.85 N.S
C/T 78 (25.7) 88 (25.7) 1.16 0.67–2.02 N.S
T/T 22 (7.3) 17 (5.0) 1.70 0.77–3.71 N.S
G/G C/C 16 (5.3) 18 (5.2) 1.17 0.51–2.64 N.S
C/T 33 (10.9) 21 (6.1) 2.06 1.01–4.22 N.S
T/T 10 (3.3) 6 (1.7) 2.19 0.71–6.65 N.S
OR: odds ratio; CI: Confidence Interval; N.S: Not Significant.
Table 4
Genotype frequencies of IL-10 polymorphisms in CAD group according to a number of affected arteries.
Genotype Control, n (%) 1 VD, n (%) p value 2 VD, n (%) p value 3 VD, n (%) p value
IL-10(819)
C/C 123 (35.9) 30 (27.0) – 18 (23.7) – 41 (35.3) –
T/C 173 (50.4) 61 (55.0) N.S 40 (52.6) N.S 56 (48.3) N.S
T/T 47 (13.7) 20 (18.0) N.S 18 (23.7) 0.017 19 (16.4) N.S
IL-10(1082)
A/A 130 (37.9) 39 (34.2) – 26 (35.1) – 30 (26.1) –
G/A 168 (49.0) 53 (46.5) N.S 37 (50.0) N.S 58 (50.4) N.S
G/G 45 (13.1) 22 (19.3) N.S 11 (14.9) N.S 27 (23.5) 0.009*
VD: vessel disease; N.S: Not Significant.
* A p value of less than 0.05 was considered statistically significant.
Table 5
Comparison of IL-10 gene expression between CAD patients and healthy controls.
Groups N DCty DDCt 2DDCt = Rdh P value
IL-10(-819)
CAD patients 80 4.56 1.75 21.75 = 3.36 <0.001*
Controls 80 6.31
IL-10(-1082)
CAD patients 80 5.23 0.99 20.99 = 1.98 <0.001*
Controls 80 6.22
hRd; The ratio of the relative amount of target in CAD patients to the relative amount of target in healthy controls.
y DCt; Ave. IL-10 Ct – Ave. PGK1Ct.
 DDCt; DCtControls–DCtpatients.
* A p value of less than 0.05 was considered statistically significant.
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